Protein (1)
Launched (1)
Human (1)
Fc Tag (1)
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
ILI-H5253 | HEK293 | Human IL-1 RI Protein, Fc Tag (MALS verified) | ![]() |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| ACT-01 | ACT-01; OCS-05; BN-201; G-79 | Phase 2 Clinical | Promius Pharma | Keratosis, Actinic; Optic Neuritis; Demyelinating Diseases | Details |
| Xentuzumab | BI-836845 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Dusigitumab | MEDI-573 | Phase 2 Clinical | Medimmune Llc | Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular | Details |

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호




